Corporate Information

LIFE: The European Patent Office intends to issue new Lifecare patent

Posted: 08/11/2023
LIFE: The European Patent Office intends to issue new Lifecare patent

Bergen, Norway, November 8th, 2023: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces that the European Patent Office (EPO) has reported its intent to grant Lifecare a new patent.

Lifecare will review the examining division’s comments to the patent application and respond to the EPO for their final review and granting of the patent. Lifecare expects the EPO to announce the granting of patent within the next 6 months.

The present application relates to chemistry compositions, in special active fluid compositions which may be used in glucose sensor systems, for example a glucose sensor which relies on osmotic pressure as sensing principle. The chemistry composition is a fundamental addition to Lifecare’s Sencell-technology and an important part for Lifecare’s further development and commercialization.

– In light of existing and granted patents for Lifecare’s sensor technology, this will strengthen our commercial position for accurate and continuous monitoring of glucose, for people with diabetes, says CEO Joacim Holter.

This new patent will strengthen Lifecare’s technology protection until 2037.

– Existing continuous glucose measurement technologies are inconvenient, complicated, costly, and have limited lifetime. The Sencell system together with the active fluid composition according to the invention has advantageous effect on sensor lifetime, measurement response time, and measurement sensitivity, says Lifecare CSO, Prof. Dr. Dr. Med. Andreas Pfützner.

About us
Lifecare AS is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare’s main focus is to bring the next generation of Continuous Glucose Monitoring (“CGM”) systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors (“NTR”) on the sensor body for read-out of pressure variations. Lifecare’s sensor technology is referred to as “Sencell” and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body.

Contacts
For further information, please contact:

Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40

Asle Wingsternes, Head of Communications & Public Affairs, asle.wingsternes@lifecare.no, +47 41 61 42 52

This information has been submitted pursuant to the Securities Trading Act § 5-12 and MAR Article 19 no. 3. The information was submitted for publication at 2023-11-08 08:00 CET.

Attachments
LIFE: The European Patent Office intends to issue new Lifecare patent

LIFE: The European Patent Office intends to issue new Lifecare patent